Physician

Family Medicine

Gary L. Legler, DO practices Family Medicine. Gary Legler is also a published MD. He has 69 publication published. The most recent publication is: The Gaucher mouse: differential action of conduritol B epoxide and reversibility of its effects. He is registered with Medicare.

Publications

---

• Purification and characterization of a microsomal bile acid beta-glucosidase from human liver.
• N1-alkyl-D-gluconamidines: are they ''perfect'' mimics of the first transition state of glucosidase action?
• A novel approach to the 1-deoxynojirimycin system: synthesis from sucrose of 2-acetamido-1, 2-dideoxynojirimycin, as well as some 2-N-modified derivatives.
• Processing of epidermal glucosylceramides is required for optimal mammalian cutaneous permeability barrier function.
• [Sugar analog inhibitors for glycosidases, tools for the elucidation of enzymatic hydrolysis of glycosides].
• Mechanism of enzymic glycoside hydrolysis and of glycosyl transfer by glycosidases and glycosyltransferases.
• The role of the hydroxy amino acid in the triplet sequence Asn-Xaa-Thr(Ser) for the N-glycosylation step during glycoprotein biosynthesis.
• Conformational aspects of N-glycosylation of proteins. Studies with linear and cyclic peptides as probes.
• The use of inhibitors in the study of glycosidases.
• The Gaucher mouse.
• Distribution of conduritol B epoxide in the animal model for Gaucher''s disease (Gaucher mouse).
• Role of sugar hydroxyl groups in glycoside hydrolysis. Cleavage mechanism of deoxyglucosides and related substrates by beta-glucosidase A3 from Aspergillus wentii.
• Isolation and structure of a tryptic glycopeptide from the active site of beta-glucosidase A3 from Aspergillus wentii.
• Inhibition of formation of complex oligosaccharides by the glucosidase inhibitor bromoconduritol.
• Effect of inhibitors of glycosylation on proteolytic activation of avian influenza virus hemagglutinins: discrimination between tryptic cleavage and elimination of the...
• Identification of an essential carboxylate group at the active site of lacZ beta-galactosidase from Escherichia coli.
• Active site-directed inhibition of galactosidases by conduritol C epoxides (1,2-anhydro-epi- and neo-inositol).
• The effect of deoxymannojirimycin on the processing of the influenza viral glycoproteins.
• Purification by affinity chromatography of glucosidase I, an endoplasmic reticulum hydrolase involved in the processing of asparagine-linked oligosaccharides.
• Synthesis of 5-amino-5-deoxy-D-mannopyranose and 1,5-dideoxy-1,5-imino-D-mannitol, and inhibition of alpha- and beta-D-mannosidases.
• Inhibition of N-linked oligosaccharide trimming does not interfere with surface expression of certain integral membrane proteins.
• Novel mannosidase inhibitor blocking conversion of high mannose to complex oligosaccharides.
• Effects of the glucosidase inhibitors nojirimycin and deoxynojirimycin on the biosynthesis of membrane and secretory glycoproteins.
• Inhibition by nojirimycin and 1-deoxynojirimycin of microsomal glucosidases from calf liver acting on the glycoprotein oligosaccharides Glc1-3Man9GlcNAc2.
• The effect of flavomycin on the synthesis and transfer of lipid-linked saccharides in pig brain.
• Epoxyalkyl oligo-(1 leads to 4)- -D-glucosides as active-site-directed inhibitors of cellulases.
• Isolation and amino acid sequence of a hexadecapeptide from the active site of beta-glucosidase A3 from Aspergillus wentii.
• [Investigations on the mechanism of action of glycoside splitting enzymes. VII. Functional groups at the active site of an alpha-glucosidase from Saccharomyces cerevis...
• Active site directed inhibitors and mechanism of action of glycosidases.
• [Investigations on the mechanism of glycoside-splitting enzymes, VIII. Number of active sites of the beta-glucosidases A and B from sweet almond emulsin determined by ...
• On the chemical basis of the Lowry protein determination.
• Goat liver beta-mannosidases: molecular properties, inhibition and inactivation of the lysosomal and nonlysosomal forms.
• Gaucher disease types 1, 2, and 3: differential mutations of the acid beta-glucosidase active site identified with conduritol B epoxide derivatives and sphingosine.
• Further studies on the catalytic mechanism of human liver alpha-L-fucosidase.
• The role of N-glycosylation for the plasma clearance of rat liver secretory glycoproteins.
• Active-site-directed inactivation of human liver alpha-L-fucosidase by conduritol C trans-epoxide.
• [Common properties and differences in the mechanism of action of glycoside hydrolases].
• Human acid beta-glucosidase: isolation and amino acid sequence of a peptide containing the catalytic site.
• Human acid beta-glucosidase: inhibition studies using glucose analogues and pH variation to characterize the normal and Gaucher disease glycon binding sites.
• Influence of asparagine-linked oligosaccharides on tumor cell recognition in the mixed lymphocyte reaction.
• Active site directed inhibition of a cytosolic beta-glucosidase from calf liver by bromoconduritol B epoxide and bromoconduritol F.
• Partial purification and characterization of Naegleria fowleri beta-glucosidase.
• Human acid beta-glucosidase. Use of conduritol B epoxide derivatives to investigate the catalytically active normal and Gaucher disease enzymes.
• Synthesis of 5-amino-5-deoxy-D-galactopyranose and 1,5-dideoxy-1,5-imino-D-galactitol, and their inhibition of alpha- and beta-D-galactosidases.
• The mannosidase inhibitors 1-deoxymannojirimycin and swainsonine have no effect on the biosynthesis and infectivity of Rous sarcoma virus.
• Study of beta-glucosidase from Helix pomatia by active site-directed inhibitors.
• Isolation of a cytosolic beta-glucosidase from calf liver and characterization of its active site with alkyl glucosides and basic glycosyl derivatives.
• Human acid beta-glucosidase: use of inhibitors, alternative substrates and amphiphiles to investigate the properties of the normal and Gaucher disease active sites.
• Human acid beta-glucosidase: affinity purification of the normal placental and Gaucher disease splenic enzymes on N-alkyl-deoxynojirimycin-sepharose.
• Characterization of calf liver glucosidase I and its inhibition by basic sugar analogs.
• Purification and characterization of a neutral processing mannosidase from calf liver acting on (Man)9(GlcNAc)2 oligosaccharides.
• Glucosylceramidase from calf spleen. Characterization of its active site with 4-n-alkylumbelliferyl beta-glucosides and N-alkyl derivatives of 1-deoxynojirimycin.
• Cell type dependent inhibition of transport of cathepsin D in HepG2 cells and fibroblasts exposed to deoxy-manno-nojirimycin and deoxynojirimycin.
• Intracellular activity of lysosomal glucosylceramidase measured with 4-nonylumbelliferyl beta-glucoside.
• Glycoside hydrolases: mechanistic information from studies with reversible and irreversible inhibitors.
• Bovine N-acetyl-beta-D-glucosaminidase: affinity purification and characterization of its active site with nitrogen containing analogs of N-acetylglucosamine.
• Location of the two catalytic sites in intestinal lactase-phlorizin hydrolase. Comparison with sucrase-isomaltase and with other glycosidases, the membrane anchor of l...
• 4,4''-Dinitrodiphenyldisulfides of different charge type as probes for the electrostatic environment of sulfhydryl groups.
• Recent observations on Gaucher''s disease.
• Glucosidases.
• The Gaucher mouse: additional biochemical alterations.
• Stereospecific ring opening of conduritol-B-epoxide by an active site asparatate residue of sucrase-isomaltase.
• Inhibition of beta-glucosidases from almonds by cationic and neutral beta-glucosyl derivatives.
• Amino acid sequence at the active site of beta-glucosidase A from bitter almonds.
• Reaction of beta-D-glucosidase A3 from Aspergillus wentii with D-glucal.
• The Gaucher mouse: differential action of conduritol B epoxide and reversibility of its effects.
• Studies on the possible identity of particulate beta-glucosidase and beta-xylosidase of mouse liver.
• The mechanism of action of glycosidases.

Schools

---

• Kansas City College of Osteopathic Medicine

Doctors Specialties

---

• Family Medicine

Accepted Insurances

---

Education

---

• Kansas City University of Medicine and Biosciences

Hospital

---

• The University of Kansas Hospital

Drug Facts

---

NPI NUMBER		1295782233
NPPES Provider LastName		LEGLER
NPPES Provider FirstName		GARY
NPPES Provider ZIPCode		661021748
NPPES Provider State		KS
Specialty Description		Family Practice
Total Claim Count		42.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1295782233
Last Name Of The Provider	LEGLER
First Name Of The Provider	GARY
View All

Similar Doctors

---

	Dr. Eleanor A. Lisbon, MD This Doctor is OpenDoctor Recommended.
	Dr. Joshua A. Freeman, MD This Doctor is OpenDoctor Recommended.
	Dr. Katarzyna A. Szymanek, DO This Doctor is OpenDoctor Recommended.
	Dr. Tanya N. Bedward, MD
	Dr. Keith A. Greiner Jr., MD This Doctor is OpenDoctor Recommended.
	Dr. Gregory M. Erb, MD This Doctor is OpenDoctor Recommended.
	Dr. Sabrina Markese, MD This Doctor is OpenDoctor Recommended.
	Dr. Kare H. Lyche, MD This Doctor is OpenDoctor Recommended.
	Dr. Mohammad C. Ghassemi, MD This Doctor is OpenDoctor Recommended.
	Dr. Mike S. Zuniga, MD
	Dr. Daniel C. Parra, MD

---

Doctor Directory | TOS | twitter | FB | Angel | blog